The European Commission has spent the last year agonising over its research policy. It accepts that in many respects it is not working optimally. Scientists have been asked to spend too much time form-filling and to wait too long for funding. It is concerned about rising oversubscription-chances of even highly-graded research applications actually receiving funds are falling alarmingly. On a broader level, it believes that its policy is outdated, and that in future research funds should be targeted at projects with more direct industrial and societal relevance.
A few relevant changes
Changes are already being implemented, and the commission is more recently able to claim some success at least in shortening waiting times, and even sometimes in reducing the flood of applications for limited funds by focusing down the scope of each call for proposals. The commission's formal proposal for its fifth research framework programme, which will run from 1998 to 2002, and which is now being considered by the European Parliament and the European Council, proposes an apparently radical new approach to funding. It calls for a new, complicated management system which aims to increase coordination between different programmes throughout the commission. It proposes three thematic programmes, one of which covers life sciences and the environment. Each thematic programme includes key actions, which are more precisely defined research areas, such as 'environment and health'. There are also three so-called 'horizontal' programmes, one of which is dedicated to training and mobility of scientists.
The proposal has been criticized for its vagueness. It gives little indication as to level of financing, although it states that this should not be lower than that of the current framework programme. And it gives no details about how the new management system will work in practice.
Neither dose it give any serious detail about the content of each programme or each key action. However, it seems likely that behind the mist, there are few big changes planned for cancer research, which has already had a recent policy overhaul.
Cancer research as example
These new trends in cancer research are an example of the commission's current thinking. New objectives, which were originally more orientated to basic research projects will in future include a noticeable integration with clinical research. This means interactions between molecular and cellular biological research and oncology or epidemiology, for example the application of molecular techniques to the prevention, early detection and treatment of cancer, or combining cellular or molecular genetics with multinational epidemiological studies to identify the environmental and genetic components determining carcinogenesis.
The document gives a broad range of research tasks including
• molecular mechanisms of tumorigenesis and metastasis; • control of cellular growth, differentiation and death; • selective targeting of tumour cells; • development of new models for basic and clinical research, including gene therapy; • identifying predisposition, early diagnosis, early detection of metastases; • assessing effectiveness of different systemic treatments; • developing methods for analysing efficacy of new treatments; • data collections which allow analysis on a transnational basis; • assessment of factors contributing to optimal quality of life, including terminal care. Whether or not all these topics will find a home in the fifth framework programme will be decided over the next months. If they are, it is most probable that they will have to be spread over different programmes and key actions -dedicated for example to public health research or human genome research -as the commission works to give the vague proposal currently on the table a more defined structure. It is unlikely that the total amount of money for cancer research will change significantly from the ECU 45 million that it had in the fourth framework programme. This will make it hard to resolve the problem of oversubscription. Success rate in the current cancer research programme is less than 10%, and the commission is aware that this is discouragingly low. Even to achieve this low level of grant approval, the commission has had to restrict its funding to an average of 40% of the money requested. The commission hopes that in the future more precisely defined calls for proposals will reduce the total number of applications and raise the success rate.
Details on the prospects for cancer research in the fifth framework programme should become clearer by the end of summer.
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